
FDA has now published the $REGN linvoseltamab CRL (dated 20 Aug 2024) download.open.fda.gov/crl/CR… Columvi & Talzenna are still outstanding, unless I've missed them.

Journalist @ApexOnco. The Wolverine Of Biotech / Mr ASH. Interested in: oncology. Not interested in: what stock you bought today. My internal plan is as follows

FDA has now published the $REGN linvoseltamab CRL (dated 20 Aug 2024) download.open.fda.gov/crl/CR… Columvi & Talzenna are still outstanding, unless I've missed them.

$IPHA $IPH.PA reports 1 confirmed response among 19 post-Padcev urothelial cancer pts (where it'd hoped for fast approval), as well as stomatitis as a dose-limiting toxicity. Shares down 7% this morning apexonco.com/innate-shows-bi…

Seven years later, $MRK $2.7 bn Arqule deal is a zero. Via @ApexOnco -> apexonco.com/node/2497 $LLY $ONC $NRIX $RHHBY


Never mind. It's probably just another "nothing burger". Nothing to see, no value in disclosing CRLs! $SMMT

So, er... about the FDA pausing its publication of CRLs $SMMT
Summit's CRL is a good case in point for the value of FDA disclosure. Summit's statement cited one principal reason for the FDA's rejection. The FDA's letter, posted today, cites four (see two images to right): download.open.fda.gov/crl/CR… $SMMT

Kudos to #Jefferies26 analyst for asking Akeso about the $SMMT CRL as first question. Co response: shrug, "it is what it is", US EGFRm setting is small anyway.


At #Jefferies26 Fair also noted that $MRK has changed the definition of MMR vs what Terns used. Characterised Merck as ceding the post-Scemblx setting to $ELVN

$ELVN Fair: we expect the $MRK embibatinib dataset to decline further #Jefferies26

$ELVN CEO Rick Fair says $MRK decline in MMR for embibatinib per #Ash26 abstract, vs Terns #Ash25 data, is curious. It's not just data maturing, as current dataset is less mature overall than the earlier one #Jefferies26

$IDYA Kat6/7 (IDE574) data update in 2027. Paradoxically company claims better safety than with pure Kat6 inhibition #Jefferies26

We believe we have a best-in-class PRMT5 inhibitor $IDYA #Jefferies26
$IDYA only showing 1 PR (cholangio) for PRMT5 monoTx in safety eval pop of 31 at R&D day. Still escalating, responses take a couple months with the class, but no verbage about more responses seen either.

$IDYA reiterates timeline for interim OS data in Optimum-02: mid-2027. Sounds like FDA filing will include an informal look at OS too #Jefferies26

$ZYME CEO Ken Galbraith telling #Jefferies26 this is the next evolution of VEGF x PD-1 (bispecific space is saturated, he says, and this format isn't easy to copy). R&D day 11 Feb 2027.
